Adenosine Or Derivative Patents (Class 514/46)
-
Publication number: 20090298788Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.Type: ApplicationFiled: June 18, 2009Publication date: December 3, 2009Inventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
-
Patent number: 7625875Abstract: 2? and 3?-Prodrugs of 1?, 2?, 3? or 4?-branched ?-D or ?-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: December 6, 2004Date of Patent: December 1, 2009Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, L'Universite Montpellier IIInventors: Gilles Gosselin, Richard Storer, Paola LaColla, Jean-Pierre Sommadossi
-
Patent number: 7625877Abstract: The present invention provides a 4?-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: wherein X represents a halogen atom, R1 represents an ethynyl group or a cyano group, and R2 represents hydrogen, a phosphate residue, or a phosphate derivative residue. The present invention also provides a pharmaceutical composition containing the derivative and a pharmaceutically acceptable carrier therefor. The derivative is useful as a medicine for the treatment of Acquired Immune Deficiency Syndrome (AIDS).Type: GrantFiled: November 19, 2007Date of Patent: December 1, 2009Assignee: Yamasa CorporationInventors: Satoru Kohgo, Hiroshi Ohrui, Eiichi Kodama, Masao Matsuoka, Hiroaki Mitsuya
-
Patent number: 7625876Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: August 20, 2007Date of Patent: December 1, 2009Assignee: Hopital-Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Publication number: 20090291909Abstract: A composition for the protection, treatment and repair and for reducing the inflammation of connective tissue in mammals and a method for the treatment of connective tissue in mammals by the administration of the composition. The composition includes S-Adenosylmethionine (SAM), and a component selected from an aminosugar or salts thereof (e.g., glucosamine) or glycosaminoglycans (e.g., chondroitin salts) or mixtures or fragments thereof. The composition optionally includes manganese which promotes the production of connective tissue matrix. The composition also optionally includes methyl donors or methyl donor cofactors, such as vitamin B12, vitamin B6, folic acid, dimethylglycine or trimethylglycine.Type: ApplicationFiled: May 28, 2009Publication date: November 26, 2009Applicant: NUTRAMAX LABORATORIES, INC.Inventors: Robert W. HENDERSON, Tarek Hammad
-
Patent number: 7618949Abstract: The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12 receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12 receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.Type: GrantFiled: July 30, 2008Date of Patent: November 17, 2009Assignees: Inspire Pharmaceuticals, Inc., University of North Carolina at Chapel HillInventors: José L. Boyer, James G. Douglass, III, Sammy R. Shaver
-
Publication number: 20090280059Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).Type: ApplicationFiled: July 13, 2009Publication date: November 12, 2009Applicant: PGXHEALTH, LLCInventors: Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20090280086Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: July 16, 2009Publication date: November 12, 2009Inventors: Jean-Pierre Sommadossi, Paulo LaColla
-
Publication number: 20090275529Abstract: A method of reducing the increased risk of cardiovascular events attendant with the use of COX or selective COX-2 inhibitors including restoring disrupted cholesterol metabolic function engendered by the use of the COX or selective COX-2 inhibitors and reducing the production of foam cells caused thereby. The disrupted cholesterol metabolic function is restored and the production of foam cells is reduced by the step of administering an adenosine A2A receptor agonist having a threshold level of activity of 0.1 ?M to a patient using the COX or COX-2 inhibitor. The adenosine A2A receptor agonist is administered orally in amounts sufficient to saturate the A2A receptor and at time intervals sufficient to maintain the restored cholesterol metabolic function.Type: ApplicationFiled: May 5, 2009Publication date: November 5, 2009Inventors: Allison B. Reiss, Steven Carsons
-
Patent number: 7612047Abstract: The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.Type: GrantFiled: September 10, 2008Date of Patent: November 3, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: James G. Douglass, III, Benjamin R. Yerxa, Sammy R. Shaver, Ward M. Peterson, Edward G. Brown, Christopher S. Crean, José L. Boyer
-
Patent number: 7608600Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: GrantFiled: June 27, 2003Date of Patent: October 27, 2009Assignees: Idenix Pharmaceuticals, Inc., University of Cagliari, Centre National de la Recherche Scientifique, L'Universite Montfellier IIInventors: Richard Storer, Gilles Gosselin, Jean-Pierre Sommadossi, Paola LaColla
-
Patent number: 7608601Abstract: The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.Type: GrantFiled: July 15, 2004Date of Patent: October 27, 2009Assignee: Roche Palo Alto LLCInventors: Rene Robert Devos, Christopher John Hobbs, Wen Rong Jiang, Joseph Armstrong Martin, John Herbert Merrett, Isabel Najera, Nobuo Shimma, Takuo Tsukuda
-
Patent number: 7608597Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: GrantFiled: June 20, 2003Date of Patent: October 27, 2009Assignees: Idenix Pharmaceuticals, Inc., Universita Degli Studi Di CagliariInventors: Jean-Pierre Sommadossi, Paulo LaColla
-
Publication number: 20090264383Abstract: The invention relates to use of a composition comprising an inhibitor of adenylyl cyclase in the elongation of circadian rhythm, a method of extending the period of circadian rhythm in a subject, said method comprising administering to said subject an inhibitor of adenylyl cyclase, and to adenylyl cyclase inhibitor for use in the treatment of a disorder of the circadian rhythm. Preferably the inhibitor is a P-site inhibitor, preferably 9-(tetrahydrofuryl)-adenine. The composition may further comprise a JNK inhibitor.Type: ApplicationFiled: May 18, 2007Publication date: October 22, 2009Applicant: Medical Research CouncilInventors: Michael Hastings, Elizabeth Maywood, John O'Neill
-
Patent number: 7605143Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.Type: GrantFiled: August 2, 2005Date of Patent: October 20, 2009Assignee: University of Virginia Patent FoundationInventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
-
Patent number: 7605137Abstract: This invention provides a method for treating tumor in a subject comprising administering to the subject an effective amount of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. This invention also provides a method for inhibiting tumor cell growth comprising contacting the tumor cell with effective amounts of: (1) VNP40101M, or its equivalent; and (2) a nucleoside, or a nucleoside analog. The present invention relates to the treatment of cancer, comprising administering to a subject in need thereof an effective amount of VNP40101M in combination with a nucleoside.Type: GrantFiled: March 25, 2005Date of Patent: October 20, 2009Assignee: Vion Pharmaceuticals, Inc.Inventors: Ivan King, Mario Sznol, Michael Belcourt, Li-Mou Zheng
-
EFFECTIVE DELIVERY OF CROSS-SPECIES A3 ADENOSINE-RECEPTOR ANTAGONISTS TO REDUCE INTRAOCULAR PRESSURE
Publication number: 20090258836Abstract: Provided are methods for reducing intraocular pressure in an individual having an ocular disorder causing elevated intraocular pressure, such as glaucoma. The method comprises administering to the individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A3 subtype adenosine receptor (A3AR) antagonist, including dihydropyridine, pyridine, pyridinium salt or triazoloquinazoline, and derivatives thereof expressly having A3AR antagonist activity, including, e.g., the nucleoside-based A3AR antagonist, MRS-3820. Further provided is a method for ensuring the delivery of a topically administered therapeutic composition for reducing intraocular pressure, wherein the method expressly requires physically opening a channel through the corneal barrier of the patient's eye by a microneedle or micropipette to permit transport of the topical composition to the anterior chamber of the eye.Type: ApplicationFiled: April 6, 2009Publication date: October 15, 2009Inventors: Mortimer M. Civan, Kenneth A. Jacobson, Marcel Y. Avila, Richard Stone -
Publication number: 20090253647Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.Type: ApplicationFiled: June 18, 2009Publication date: October 8, 2009Inventors: Jayson M. Rieger, Jeol M. Linden, Timothy L. MacDonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler
-
Publication number: 20090247483Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by elevating cAMP by administering or stimulating receptors coupled to a Gs protein in an amount sufficient to decrease the elevated pHL or restore acidity of said lysosomes, specifically by administering or stimulating receptors comprising D1-like dopamine receptors by the use of D1-like dopamine receptor agonists. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.Type: ApplicationFiled: April 3, 2009Publication date: October 1, 2009Inventors: Claire Mitchell, Alan Laties
-
Patent number: 7592326Abstract: Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant.Type: GrantFiled: January 30, 2007Date of Patent: September 22, 2009Inventor: David K. R. Karaolis
-
Patent number: 7592445Abstract: This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation.Type: GrantFiled: January 4, 2008Date of Patent: September 22, 2009Assignee: Inspire Pharmaceuticals, Inc.Inventors: Robert Plourde, Jr., Sammy R. Shaver, James G. Douglass, III, Paul S. Watson, José L. Boyer, Chi Tu, Melwyn A. Abreo, Lorenzo J. Alfaro-Lopez, Yangbo Feng, Daniel F. Harvey, Tatyana V. Khasonova
-
Publication number: 20090233878Abstract: The present invention provides compounds of the formula wherein Ar, R and R1 have a meaning as defined herein in the specification. Compounds of formula (I) are agonists of the A3 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A3 adenosine receptor. Accordingly, the compounds of formula (I) may be employed for treatment of behavioral depression, cerebral ischemia, hypotension, chemically induced seizures, inflammatory diseases, asthma, and cancer diseases expressing the adenosine A3 receptor.Type: ApplicationFiled: August 29, 2008Publication date: September 17, 2009Inventors: Pier Giovanni Baraldi, Allan R. Moorman, Pier Andrea Borea
-
Publication number: 20090233879Abstract: The present patent application relates to the novel nucleoside derivatives and novel intermediates, which are useful to antiviral, anti tumor and immunomodulatory activity, method of treating diseases, conditions and/or disorders modulated by viral infections with them, and processes for preparing them.Type: ApplicationFiled: March 12, 2009Publication date: September 17, 2009Applicant: HETERO DRUGS LIMITEDInventors: Bandi Parthasaradhi REDDY, Vedula Manohar SHARMA, Kura Rathnakar REDDY, Musku Madhanmohan REDDY, Jennepalli SREENU, Aryasomayajula RATNAKAR
-
Patent number: 7589076Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).Type: GrantFiled: May 17, 2007Date of Patent: September 15, 2009Assignee: PGx Health, LLCInventors: Jayson M. Rieger, Robert D. Thompson
-
Patent number: 7585850Abstract: The invention is directed to compositions and methods which permit the oral use of adenosine and adenosine phosphates for cardiovascular applications such as pulmonary artery hypertension, cardiac failure and other diseases. Certain compositions in accordance with the invention have enhanced AMP gastrointestinal bioavailability and thus efficacy. The invention prolongs the activity of adenosine and adenosine phosphates when administered intravenously. In particular, the invention contemplates methods of treating several human (as well as animal) cardiovascular and neurological medical conditions that could be improved by an effective amount of adenosine, ATP or AMP combined with dialkylaminoalcohols and their salts.Type: GrantFiled: February 9, 2005Date of Patent: September 8, 2009Assignee: Adenobio N.V.Inventor: Philipe Gorny
-
Publication number: 20090221521Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).Type: ApplicationFiled: February 26, 2009Publication date: September 3, 2009Applicant: Alseres Pharmaceuticals, Inc.Inventors: Mark R. Hurtt, Noel James Cusack, Richard M. Thorn
-
Publication number: 20090220516Abstract: This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X7 and A3 receptors on ganglion cells, by reducing levels of ATP released into the extracellular space of the retina and enhancing the conversion of released extracellular ATP into adenosine.Type: ApplicationFiled: June 21, 2006Publication date: September 3, 2009Inventors: Alan Laties, Claire Mitchell
-
Patent number: 7582617Abstract: The present invention provides a method for using the partial adenosine A2A receptor agonists having the following structure in myocardiological perfusion imaging.Type: GrantFiled: March 2, 2005Date of Patent: September 1, 2009Assignee: CV Therapeutics, Inc.Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
-
Publication number: 20090215714Abstract: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder.Type: ApplicationFiled: June 10, 2005Publication date: August 27, 2009Inventors: Perry Renshaw, Bruce Cohen
-
Publication number: 20090209480Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: January 17, 2007Publication date: August 20, 2009Applicant: The Regents of the University of ColoradoInventors: Daniel J. Abrams, Raymond Bunch, Tom Anchordoquy, Karen E. Stevens
-
Patent number: 7576068Abstract: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.Type: GrantFiled: September 1, 2004Date of Patent: August 18, 2009Assignee: Anadys Pharmaceuticals, Inc.Inventor: Devron R. Averett
-
Patent number: 7576069Abstract: The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described herein.Type: GrantFiled: August 2, 2005Date of Patent: August 18, 2009Assignee: University of Virginia Patent FoundationInventors: Jayson M. Rieger, Joel M. Linden, Timothy L. Macdonald, Gail W. Sullivan, Lauren J. Murphree, Robert Alan Figler, Robert Douglas Thompson
-
Publication number: 20090203637Abstract: The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.Type: ApplicationFiled: January 15, 2009Publication date: August 13, 2009Inventors: Michal Hocek, Petr Naus
-
Publication number: 20090203638Abstract: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and dyslipidemia. In still further preferred aspects, compounds with cytokinin activity are used to activate AMPK and/or Akt. Consequently, various diseases associated with dysregulation of AMPK and/or Akt may be treated using the compounds of the present inventive subject matter.Type: ApplicationFiled: April 7, 2009Publication date: August 13, 2009Applicant: VDF FUTURECEUTICALS, INC.Inventors: Dusan Miljkovic, Jovan Hranisavljevic, Zbigniew Pietrzkowski
-
Publication number: 20090197825Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: November 26, 2008Publication date: August 6, 2009Applicant: ARDEA BIOSCIENCES, INC.Inventors: Barry D. QUART, Jean-Luc GIRARDET, Esmir GUNIC, Li-Tain YEH
-
Publication number: 20090197824Abstract: Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to treat alcoholic liver disease, fatty liver disease, hepatitis, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, and depressive disorders such as depression (e.g. major clinical depression) and dysthymia.Type: ApplicationFiled: July 17, 2008Publication date: August 6, 2009Applicant: METHYLATION SCIENCES INTERNATIONAL SRLInventors: Joshua Freedman, Aviva Revgev, Nancy Harrison, Robert Miller, David MacDonald
-
Patent number: 7566703Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20090185973Abstract: Methods are presented for concurrent or sequential administration of pharmaceutical compositions of adenosine, dipyridamole, or combinations thereof, at dosages below the respective single agent doses. Methods are provided for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. Methods include sequential administration of a dipyridamole bolus followed by intravenous infusion of adenosine and concurrent administration of adenosine and dipyridamole with or without dipyridamole pretreatment. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.Type: ApplicationFiled: January 9, 2009Publication date: July 23, 2009Applicant: ADENOBIO N.V.Inventor: Philippe Gorny
-
Patent number: 7563779Abstract: This invention provides therapeutic compositions and combinations for the protection, treatment and repair of liver tissue. The invention relates to novel compositions and combinations comprising two or more compounds selected from the group consisting of S-adenosylmethionine, L-ergothioneine, and a substance selected from the group consisting of constituents of Milk thistle (Silybum marianum), silymarin and active components of silymarin, whether naturally, synthetically, or semi-synthetically derived, and to methods of preventing and treating liver disease and of repairing damaged liver tissue. The invention also provides a method of administering these compositions and combinations to humans or animals in need thereof.Type: GrantFiled: January 19, 2005Date of Patent: July 21, 2009Assignee: Nutramax LaboratoriesInventors: Todd R. Henderson, Barbara E. Corson
-
Patent number: 7557092Abstract: Disclosed are compositions and methods for modulating odor sensitivity, as well as screening methods for detecting compounds that modulate odor sensitivity.Type: GrantFiled: November 21, 2003Date of Patent: July 7, 2009Assignee: University of Utah Research FoundationInventors: Mary Lucero, Colleen Hegg
-
Patent number: 7557093Abstract: The invention provides a composition for promoting collagen production, and more specifically, provides a composition capable of promoting collagen production in human dermis. Further, the invention provides a method for promoting collagen production. The invention provides a composition for promoting collagen production containing a purine nucleic acid-related substance as an active ingredient as well as a composition for promoting collagen production containing a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance. The method for promoting collagen production of the invention comprises applying a purine nucleic acid-related substance alone or in combination with a pyrimidine nucleic acid-related substance to the skin.Type: GrantFiled: October 8, 2004Date of Patent: July 7, 2009Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeo Shinohara, Mitsuaki Kawamura
-
Publication number: 20090170805Abstract: Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5?-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems.Type: ApplicationFiled: April 14, 2006Publication date: July 2, 2009Inventors: Derek Shieh Tan, Luis E. N. Quadri, Jae-Sang Ryu, Justin Scott Cisar, Julian Alberto Ferreras, Xuequan Lu
-
Publication number: 20090169504Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: April 25, 2008Publication date: July 2, 2009Inventors: Jean-Pierre Sommadossi, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
-
Patent number: 7553823Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.Type: GrantFiled: September 15, 2006Date of Patent: June 30, 2009Assignee: CV Therapeutics, Inc.Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
-
Publication number: 20090162292Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: ApplicationFiled: December 18, 2008Publication date: June 25, 2009Applicant: PGXHEALTH, LLCInventors: Robert D. Thompson, Anthony Beauglehole, Frank Schmidtmann, Jayson M. Rieger
-
Publication number: 20090162282Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: ApplicationFiled: December 18, 2008Publication date: June 25, 2009Inventors: Robert Douglas Thompson, Anthony Beauglehole, Frank W. Schmidtmann, Jayson M. Rieger
-
Patent number: 7550442Abstract: Compounds of formula (XXIII), or pharmaceutically acceptable salts or esters thereof, are inhibitors of reverse transcriptase: R4 is a nucleoside with Q substituting a 3? hydroxyl group, and Q is a moiety of formulas (XXIV)-(XXXII):Type: GrantFiled: May 19, 2004Date of Patent: June 23, 2009Assignee: The Board of Trustees of the University of IllinoisInventors: Raven H. Huang, Xianjun Liu
-
Publication number: 20090156544Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.Type: ApplicationFiled: February 23, 2009Publication date: June 18, 2009Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
-
Publication number: 20090149416Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.Type: ApplicationFiled: February 10, 2009Publication date: June 11, 2009Inventors: Dennis C. Liotta, Shuli Mao, Michael Hager
-
Publication number: 20090123510Abstract: The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.Type: ApplicationFiled: November 10, 2008Publication date: May 14, 2009Inventors: Bruce N. Cronstein, Zhong Sheng Peng